ELVN affiliate files Form 144 to sell common shares

The Biotech Growth Trust PLC reported proposed sales of Common Stock under a Form 144.

Rhea-AI Filing Summary

The Biotech Growth Trust PLC reported proposed sales of Common Stock under a Form 144. The filing lists proposed brokered sales of 29,385 shares through Jefferies LLC and 1,747 shares through Morgan Stanley & Co. LLC. The filing also records a prior sale of 10,243 shares on 06/15/2026 for $461,139.86. Shares outstanding are shown as 69,822,989 as of 06/22/2026.

Insights

Securities Compliance Attorney

Form 144 notifies proposed resale of registered securities by an affiliate.

Form 144 is a statutory notice for proposed sales under the Securities Act. The filing identifies brokerage channels (Jefferies, Morgan Stanley) and specific share amounts, which are typical required disclosures when an affiliate proposes to sell restricted or control securities.

Timing and sale mechanics are not detailed beyond broker names; subsequent Form 4 or transaction confirmations would document completion and exact proceeds.

Capital Markets Analyst

Reported quantities are modest relative to reported outstanding shares.

The filing shows proposed brokered amounts of 29,385 and 1,747 shares alongside a recent sale of 10,243 shares. Against the stated 69,822,989 shares outstanding, these are small on an absolute basis.

Market impact depends on execution method and timing; the filing lists brokerage firms but does not specify distribution methods or planned dates for the listed brokered sales.

Key Figures

Jefferies-listed shares: 29,385 shares Jefferies-listed proceeds: $1,350,534.60 Morgan Stanley-listed shares: 1,747 shares +3 more

6 metrics

Jefferies-listed shares 29,385 shares broker entry dated 06/22/2026

Jefferies-listed proceeds $1,350,534.60 dollar amount adjacent to Jefferies entry dated 06/22/2026

Morgan Stanley-listed shares 1,747 shares broker entry dated 06/22/2026

Morgan Stanley-listed proceeds $80,292.12 dollar amount adjacent to Morgan Stanley entry dated 06/22/2026

Prior sale within 3 months 10,243 shares sold on 06/15/2026 for $461,139.86

Shares outstanding 69,822,989 shares as of 06/22/2026 shown in broker rows

Key Terms

Form 144, Securities Sold During The Past 3 Months, Shares outstanding

3 terms

Form 144 regulatory

"reported proposed sales of Common Stock under a Form 144"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Securities Sold During The Past 3 Months regulatory

"The Biotech Growth Trust PLC ... Common Stock | 06/15/2026 | 10243"

Shares outstanding financial

"69822989 | 06/22/2026 | Nasdaq Stock Market"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ELVN's Form 144 disclose?

It discloses proposed resale of Common Stock by The Biotech Growth Trust PLC. The filing lists brokered quantities of 29,385 and 1,747 shares and a recent sale of 10,243 shares on 06/15/2026 for $461,139.86.

How many shares are listed as outstanding in the filing for ELVN?

The filing shows 69,822,989 shares outstanding as of 06/22/2026. That figure appears next to broker entries for Jefferies and Morgan Stanley and provides a baseline for scale comparisons.

Who are the brokers named in ELVN's Form 144?

Jefferies LLC and Morgan Stanley & Co. LLC are named as brokers. The filing ties specific share quantities and dollar amounts to each broker entry on 06/22/2026.

Has ELVN recorded any recent sales in the filing?

Yes. The filing records a sale of 10,243 shares on 06/15/2026 with proceeds of $461,139.86. That prior sale is listed under 'Securities Sold During The Past 3 Months.'

Do the Form 144 entries confirm the sales have completed for ELVN?

No. Form 144 notifies proposed resales and lists prior sales within three months; it does not by itself confirm completion of the brokered transactions. Completion would be shown in subsequent transaction reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 08:08 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001157524
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 Lookout Road Boulder COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	The Biotech Growth Trust PLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Jefferies LLC 520 Madison Ave New York NY 10022	29385	1350534.60	69822989	06/22/2026	Nasdaq Stock Market
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	1747	80292.12	69822989	06/22/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2023	Merger	Issuer			31132	02/23/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The Biotech Growth Trust PLC 601 Lexington Ave 54th Floor New York NY 10022	Common Stock	06/15/2026	10243	461139.86

144: Remarks and Signature

Remarks	OrbiMed Capital LLC is the portfolio manager of The Biotech Growth Trust PLC.
Date of Notice	06/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Capital LLC, portfolio manager of The Biotech Growth Trust PLC
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)